Octreotide is a laboratory-made copy of a natural body chemical called somatostatin, which is a hormone that slows down many other hormones in the body. It belongs to a group of medicines made from small chains of building blocks called peptides. Doctors use it for people whose bodies make too much of certain hormones. This includes people with a growth condition called acromegaly and people with rare tumors that release hormones.
Octreotide works by attaching to the same spots on cells that the natural hormone uses. When it locks onto these spots, it tells the body to make less growth hormone and less of the hormones that control the gut. This can lower swelling, slow down gut fluids, and ease symptoms caused by hormone-releasing tumors. It is also useful in finding certain tumors, because the spots it attaches to sit on the surface of many tumor cells.
Like any strong medicine, octreotide has limits. The evidence for its main uses comes from many years of clinical practice in hospitals, but how well it works can differ from person to person. It can cause stomach problems like gas, loose stools, and discomfort. Because it is a prescription drug given by a doctor, people should never use it on their own or buy it from unclear sources. Anyone thinking about it should talk with a licensed medical provider first.
Benefits
The benefits people report — backed by research.
You just read the research on Octreotide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Every claim above traces back to a source you can check — here are 2 of them.
(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Timeline
Key moments in Octreotide’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions Octreotide.
Fierce Pharma reports FDA approval of MYCAPSSA (oral octreotide) as the first oral therapy for acromegaly maintenance, following a 2016 complete response and a patient-advocacy-driven refile. The piece details launch pricing at $5,152 per 28-day course and Chiasma's switch to a subscription model.
Pharmacy Times video interview with Rodney Pommier, MD, FACS (Oregon Health & Science University) on his 2021 NANETS symposium presentation of a prospective study managing carcinoid crisis without perioperative octreotide. The piece reports surgical-outcome data challenging the routine prophylactic octreotide bolus before carcinoid surgery.
Teva announced the U.S. launch of the first generic of Sandostatin LAR Depot (octreotide acetate) for injectable suspension, the long-acting somatostatin analog used in acromegaly and carcinoid-syndrome symptom control. The release cites reference-product annual sales of $826 million as of July 2024 and frames the first-to-market generic as a complex-formulation milestone.
Wondering how Octreotide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Compare
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.